Kyverna Therapeutics’ $319 Million Upsized IPO

Sonia Carcano
Tagged:

Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering.Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies…

This content is for Standard 1 Year members only.
Login Join Now
Sonia Carcano

Author: Sonia Carcano

…

This content is for Standard 1 Year members only.
Login Join Now